Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days

Creative Medical Technology Holdings, Inc.

Contributing Author

Recent Articles by Creative Medical Technology Holdings, Inc.

Aug-20	Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning CELZ +14.29% GlobeNewswire
Aug-06	Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz, CELZ-101 and CELZ-201 Diabetes Platforms CELZ +71.95% GlobeNewswire
Jul-01	Creative Medical Technology Holdings Issues Mid-Year Update CELZ -12.41% GlobeNewswire
Jun-30	Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.5 Million Gross Proceeds CELZ +78.97% GlobeNewswire
Jun-22	Creative Medical Technology Holdings Expands ADAPT Trial Under New FDA Clearance and Rapidly Advances Toward Phase 3 Planning for Olastrocel in Chronic Lower Back Pain CELZ -13.45% GlobeNewswire
Jun-16	Creative Medical Technology Holdings, Inc. Advances Project PHOENIX into Nationwide AI Driven Virtual Data Collection Phase for U.S. Veterans Exposed to Burn Pits and Toxic Hazards CELZ -6.28% GlobeNewswire
Apr-28	Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies CELZ GlobeNewswire
Feb-10	Creative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline CELZ GlobeNewswire
Jan-13	Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain CELZ -11.22% GlobeNewswire
Jan-06	Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative CELZ +9.31% GlobeNewswire
Dec-17	Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point CELZ GlobeNewswire
Dec-02	Creative Medical Technology Holdings Announces World Health Organization Approval of "olastrocel" as INN for Lead Allogeneic Cell Therapy CELZ-201 CELZ -11.75% GlobeNewswire
Oct-30	Creative Medical Technology Holdings, Inc. Ignites Next-Gen Regenerative BioDefense Initiative for U.S. Veterans Exposed to Burn Pits CELZ -13.03% GlobeNewswire
Oct-29	Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.2 Million Gross Proceeds CELZ -32.74% GlobeNewswire
Oct-27	Creative Medical Technology Holdings Issues Letter to Shareholders CELZ +5.43% GlobeNewswire
Oct-07	Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs CELZ GlobeNewswire
Aug-13	Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT - Advancing Breakthrough Therapy for Chronic Lower Back Pain CELZ GlobeNewswire
Jul-17	Creative Medical Technology Holdings Receives Notice of Allowance for the Prevention and/or Treatment of Type 1 Diabetes Using Modulated Immune Cells CELZ GlobeNewswire

Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)